QPPV.COM KNOWLEDGE ASSESSMENT

Eculizumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Eculizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which set of findings most directly supports investigation of suspected recurrent aHUS during eculizumab treatment?

Platelet count, haemolysis markers, renal function, blood pressure and evidence of organ injury Visual acuity, optic-nerve MRI and AQP4-antibody status Bulbar function, respiratory muscle strength and myasthenia gravis score Meningococcal serogroup, vaccination date and infusion reaction grading

Question 2 of 10 Why can eculizumab provide benefit in several diseases while producing a shared risk of meningococcal infection?

The diseases all have the same initiating pathology, and meningococci are directly targeted by the antibody The diseases share terminal-complement-mediated injury, while terminal complement also contributes to defence against meningococci Eculizumab suppresses antibody production in all indications, causing identical infection risks The drug eliminates all complement activity, so every bacterial infection is equally associated with treatment

Question 3 of 10 Which pregnancy-case approach is most consistent with the article's pharmacovigilance principles?

Record pregnancy exposure only as a special-situation code Capture gestational timing, disease activity, dosing, relevant concomitant treatment, maternal complications, delivery and neonatal outcome Exclude pregnancy cases from routine safety review because the disease is rare Assess only whether the last infusion occurred before conception

Question 4 of 10 Which pharmacovigilance approach is most appropriate when evaluating a report of possible eculizumab treatment failure?

Apply one generic lack-of-efficacy definition across all indications Assess only the time since the last dose, because clinical phenotype is not indication-specific Use the relevant disease phenotype and objective markers together with exposure and trigger assessment Assume that any clinical deterioration proves inadequate C5 blockade

Question 5 of 10 Which evidence is particularly important before classifying a reported NMOSD event as an eculizumab breakthrough relapse?

A confirmed decrease in haemoglobin and increased reticulocytes Neurological localisation, relevant imaging, AQP4-antibody context and specialist diagnostic confirmation A documented infusion reaction during the previous dose A positive blood culture for any encapsulated organism

Question 6 of 10 Which statement best describes the relationship between meningococcal vaccination and eculizumab-associated risk?

Vaccination removes the need for clinical monitoring for meningococcal disease Vaccination reduces risk but does not abolish susceptibility while terminal complement remains inhibited Vaccination is relevant only for patients treated for PNH Vaccination prevents all serious infections associated with eculizumab

Question 7 of 10 Which case documentation would best support evaluation of worsening AChR-antibody-positive generalised myasthenia gravis?

Only the patient's haemoglobin and LDH values Anatomical and functional weakness, including bulbar or respiratory involvement, plus precipitating factors and rescue treatment Only the eculizumab batch number and storage temperature Meningococcal culture results without neurological assessment

Question 8 of 10 Which description best captures eculizumab's pharmacological classification?

A small-molecule inhibitor of the alternative complement pathway A humanised monoclonal antibody that inhibits terminal complement by binding C5 A recombinant replacement for the PIGA gene product A monoclonal antibody that neutralises C5a after it has been formed

Question 9 of 10 A patient develops dyspnoea, rash and hypotension during an eculizumab infusion. What is the most appropriate pharmacovigilance interpretation?

The event is automatically a disease relapse The event is automatically meningococcal sepsis The event should be reconstructed against infusion timing and assessed for infusion reaction, hypersensitivity, infection and other causes The event can be excluded because intravenous biologics do not cause acute reactions

Question 10 of 10 Which documentation is most important for biological-product traceability in an eculizumab case?

The patient's preferred infusion appointment time The exact product identity and batch number where available Only the therapeutic class Only the indication and country of residence

Eculizumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings